Parallel Advice: A False Step in March to Globalized New Drug Reviews?
This article was originally published in RPM Report
Executive Summary
Few manufacturers are taking advantage of a program under which FDA and European regulators work together to provide scientific advice to drug developers. Now the agency is wondering whether it should end the program.
You may also be interested in...
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.
FDA-EMA Parallel Scientific Advice Program For Complex Generics Could Add Health Canada
Preliminary discussions are ongoing about adding Health Canada to the program intended to foster streamlined complex generic approval and increase access.
Complex Generic Sponsors Not Using US FDA-EMA Parallel Scientific Advice Program
After nearly two years, the program has received only two requests, driving FDA officials to try to boost interest.